Spain’s migrant crisis reopens deep EU rifts

西班牙移民危机再次揭开欧盟深层次裂痕

FT News Briefing

2026-08-03

11 分钟
PDF

单集简介 ...

UK drugmaker AstraZeneca is in talks to combine with US rival Bristol Myers Squibb, and European governments will hold an online meeting to discuss Spain’s migrant crisis. Plus, wildfires and heatwaves in Europe have already cost more than €3bn this year.  Mentioned in this podcast: AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up EU ministers to discuss Spain’s migrant crisis after Sánchez hits out over criticism Europe’s fire costs mount to beyond €3bn, FT analysis shows Hungary braced for power cuts amid extreme drought Want to get in touch? Email us at podcasts@ft.com Note: The FT does not use generative AI to voice its podcasts  The FT News Briefing is produced by Victoria Craig, Sonja Hutson, Saffeya Ahmed, Katya Kumkova, and Fiona Symon. Our editor is Marc Filippino. Our show is mixed by Sam Giovinco and Alex Higgins. Additional help from Gavin Kallmann, Michael Lello, Peter Barber and David da Silva. Our intern is Cole van Miltenburg. Our executive producer is Topher Forhecz. Flo Phillips is the FT’s global head of audio. The show’s theme music is by Metaphor Music.  Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.
更多

单集文稿 ...

  • Good morning from the Financial Times.

  • Today is Monday, August 3rd, and this is your FT News Briefing.

  • We have the scoop on mega merger talks in the pharmaceutical industry,

  • and new analysis breaks down the cost of wildfires ravaging Europe.

  • Plus, Spain's migrant crisis is reopening deep divisions in the EU.

  • I think some governments will use this to push some of their more hardline policies.

  • I'm Victoria Craig, and here's the news you need to start your day.

  • AstraZeneca and Bristol-Myers Squibb have held talks to create the world's fourth biggest pharmaceutical company.

  • A tie-up would forge a $400 billion

  • giant in the industry and would help expand AstraZeneca's footprint in the United States.

  • Aaron Kirchfeld is part of the team that broke that story for the FT.

  • He joins me now.

  • Hi, Aaron.

  • Hi there.

  • So how advanced are these discussions?

  • What do we know about this so far?

  • So according to our sources, these talks have been going on for some time.

  • And like all deals, it's always hard to predict whether they'll reach a deal or not.

  • But it sounds like if things go smoothly, according to our sources,

  • that we could see something materialize in the near term.